Showing results (81-90 of 184) with videos related to

Sort By:
Pageof 19
Transplantation|March 22, 2002
Angiotensin converting enzyme inhibition in chronic allograft nephropathyJulie Lin, Anthony M Valeri, Glen S Markowitz, et al.
Kidney International Reports|December 22, 2025
Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in ManagementJonathan Barratt, Laura H Mariani, Jai Radhakrishnan, et al.
Journal of the American Society of Hypertension : JASH|September 22, 2012
Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapyAndrew S Bomback, Yelena Rekhtman, Philip J Klemmer, et al.
Kidney International|November 6, 2009
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritisJai Radhakrishnan, Dimitrios-Anestis Moutzouris, Ellen M Ginzler, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 19, 2003
Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicityR Graham Barr, Stephen Seliger, Gerald B Appel, et al.
American Journal of Nephrology|June 23, 2012
Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trialAndrew S Bomback, Pietro A Canetta, Laurence H Beck, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 12, 2014
IgA nephropathy with minimal change diseaseLeal C Herlitz, Andrew S Bomback, Michael B Stokes, et al.
Clinical Nephrology|May 4, 2012
Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney disease and symptomatic heart failure with reduced ejection fractionAnjali Ganda, Shepard D Weiner, Neelesh L Chudasama, et al.
Frontiers in Nephrology|April 1, 2025
The kidney injury biomarker profile of patients with lupus nephritis remains unchanged with the second-generation calcineurin inhibitor voclosporinBiff F Palmer, James A Tumlin, Jai Radhakrishnan, et al.
British Journal of Haematology|March 10, 2023
First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapyRajshekhar Chakraborty, Cara Rosenbaum, Gurbakhash Kaur, et al.
Pageof 19